Want to see CH:PPGN full AI Analyst Report?
PPGN Stock Chart & Stats
CHF43.75
CHF0.05(0.11%)
At close: 4:00 PM EDT
CHF43.75
CHF0.05(0.11%)
Day’s Range― - ―
52-Week RangeCHF21.80 - CHF50.10
Previous CloseN/A
Volume526.45K
Average Volume (3M)34.07K
Market Cap
CHF1.45B
Enterprise ValueCHF913.55
Total Cash (Recent Filing)CHF74.53M
Total Debt (Recent Filing)CHF130.46M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Aug 13, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding33,125,000
10 Day Avg. Volume33,840
30 Day Avg. Volume34,067
Financial Highlights & Ratios
PEG Ratio-5.17
Price to Book (P/B)2.72
Price to Sales (P/S)2.36
P/FCF Ratio-30.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF40.67Price Target Upside-7.05% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)0.78
Revenue Forecast (FY)CHF491.57M
Bulls Say, Bears Say
Bulls Say
CDMO Business ModelA focused CDMO model serving peptide and oligonucleotide APIs creates durable demand from pharma/biotech clients that outsource complex chemistry. End-to-end services from development through commercial supply support sticky, recurring relationships and higher lifetime customer value.
Consistent Revenue GrowthSustained revenue expansion supports better capacity utilization and provides a platform to scale margins as commercial programs ramp. Consistent top-line growth across years helps underpin investments in capacity and technical capabilities tied to long-term service demand.
Improving Operating Cash Flow And Moderate LeverageStronger operating cash flow improves the firm's ability to fund operations and incremental investment despite reported losses. Combined with a moderate debt-to-equity range (~0.26–0.30 historically), this provides financial flexibility to support growth and handle project working-capital cycles.
Bears Say
Persistent Net LossesOngoing net losses indicate the company has not fully converted operational recovery into bottom-line profitability. Persistent losses erode equity, limit retained-capital funding for expansion, and can increase reliance on external financing during multi-year investment cycles in CDMO capacity.
Volatile Free Cash FlowSharp swings in free cash flow reduce predictability for capital allocation and may force periodic external funding. For a capital-intensive CDMO, inconsistent FCF complicates capacity investment timing and increases refinancing or liquidity risk over the medium term.
Rising Leverage And Declining EquityAn increasing debt-to-equity trend weakens financial flexibility and heightens interest-rate and refinancing exposure. Declining equity from cumulative losses reduces the cushion against operational shocks and can constrain the company's ability to fund strategic capacity builds without raising additional capital.
PolyPeptide Group AG News
PPGN FAQ
What was PolyPeptide Group AG’s price range in the past 12 months?
PolyPeptide Group AG lowest stock price was CHF21.80 and its highest was CHF50.10 in the past 12 months.
What is PolyPeptide Group AG’s market cap?
PolyPeptide Group AG’s market cap is CHF1.45B.
When is PolyPeptide Group AG’s upcoming earnings report date?
PolyPeptide Group AG’s upcoming earnings report date is Aug 13, 2026 which is today.
How were PolyPeptide Group AG’s earnings last quarter?
Currently, no data Available
Is PolyPeptide Group AG overvalued?
According to Wall Street analysts PolyPeptide Group AG’s price is currently Overvalued.
Does PolyPeptide Group AG pay dividends?
PolyPeptide Group AG pays a Notavailable dividend of CHF0.3 which represents an annual dividend yield of N/A. See more information on PolyPeptide Group AG dividends here
What is PolyPeptide Group AG’s EPS estimate?
PolyPeptide Group AG’s EPS estimate is 0.07.
How many shares outstanding does PolyPeptide Group AG have?
PolyPeptide Group AG has 33,125,000 shares outstanding.
What happened to PolyPeptide Group AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PolyPeptide Group AG?
Currently, no hedge funds are holding shares in CH:PPGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PolyPeptide Group AG
PolyPeptide Group AG operates globally as a contract development and manufacturing organization (CDMO), specializing in the production of Good Manufacturing Practice (GMP)-grade peptides. These peptides, available in both proprietary and generic forms, are vital for pharmaceutical and biotechnology companies, serving as key ingredients in approved medicines, compounds undergoing clinical development, and generic drug formulations. The company also produces custom research-grade peptides and actively develops neoantigen peptides to support personalized cancer therapies. Its manufacturing expertise extends to peptides used in commercially approved therapeutics, peptide-based generics for human and veterinary applications, and cosmetic peptides. Additionally, PolyPeptide Group AG provides regulatory affairs support services. Founded in 1952 and headquartered in Zug, Switzerland, the company is a subsidiary of Draupnir Holding B.V.
PPGN Stock 12 Month Forecast
Average Price Target
CHF40.67
▼(-7.05% Downside)
Technical Analysis
Lonza Group Ltd
―
Bachem Holding AG
―
Siegfried Holding AG
―
Sandoz Group Ltd
―
Galderma Group AG
―